The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.

MLA

Crassini, Kyle, et al. “The MEK1/2 Inhibitor, MEKi-1, Induces Cell Death in Chronic Lymphocytic Leukemia Cells under Conditions That Mimic the Tumor Microenvironment and Is Synergistic with Fludarabine.” Leukemia & Lymphoma, vol. 56, no. 12, Dec. 2015, pp. 3407–17. EBSCOhost, https://doi.org/10.3109/10428194.2015.1032963.

APA

Crassini, K., Stevenson, W. S., Mulligan, S. P., & Best, O. G. (2015). The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leukemia & Lymphoma, 56(12), 3407–3417. https://doi.org/10.3109/10428194.2015.1032963

Chicago

Crassini, Kyle, William S. Stevenson, Stephen P. Mulligan, and O. Giles Best. 2015. “The MEK1/2 Inhibitor, MEKi-1, Induces Cell Death in Chronic Lymphocytic Leukemia Cells under Conditions That Mimic the Tumor Microenvironment and Is Synergistic with Fludarabine.” Leukemia & Lymphoma 56 (12): 3407–17. doi:10.3109/10428194.2015.1032963.